Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)β’ Click on a phase to view related trials
AMT-116 in Patients with Solid Tumors
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Multitude Therapeutics Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT06782334
- Locations
- π¨π³
Fujian Cancer Hospital, Fuzhou, Fujian, China
π¨π³Dongguan People's Hospital, Dongguan, Guangdong, China
π¨π³Zhujiang Hospital of Southern Medical University(The Second Clinical Medical College), Guangzhou, Guangdong, China
AMT-676 in Patients With Advanced Solid Tumors
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Multitude Therapeutics Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06400485
- Locations
- π¦πΈ
Carolina Biooncology Institute, Huntersville, American Samoa
π¦πΈJohn Hopkins Sidney Kimmel Comprehensive Cancer Center, Philadelphia, American Samoa
π¦πΈSouth Texas Accelerated Research Therapeutics (start) San Antonio, San Antonio, American Samoa
AMT-253 in Patients With Advanced Solid Tumours
- Conditions
- Malignant MelanomaAdvanced Solid Tumors
- Interventions
- Drug: AMT-253 for injection
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Multitude Therapeutics Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT06209580
- Locations
- π¨π³
Beijing Cancer Hospital, Beijing, Beijing Municipality, China
AMT-116 in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Multitude Therapeutics Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05725291
- Locations
- πΊπΈ
Sarah Cannon Research Institute, Denver, Colorado, United States
πΊπΈMary Crowley Cancer Research Centers, Dallas, Texas, United States
π¦πΈCarolina BioOncology Institute, LLC, Cary, American Samoa
AMT-151 in Patients With Selected Advanced Solid Tumours
- Conditions
- Advanced Solid TumorPancreatic Ductal AdenocarcinomaEndometrial AdenocarcinomaEndometrial Serous AdenocarcinomaLung AdenocarcinomaAdvanced CancerAdvanced CarcinomaOvarian CancerOvarian CarcinomaEndometrial Clear Cell Adenocarcinoma
- Interventions
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Multitude Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05498597
- Locations
- π¦πΊ
Chris O'Brien Lifehouse, Sydney, New South Wales, Australia
π¦πΊICON Cancer Centre, Brisbane, Queensland, Australia
π¦πΊMater Cancer Care Centre, South Brisbane, Queensland, Australia